330TiP Trastuzumab deruxtecan (T-DXd; DS-8201) in HER2-positive (HER2+) and HER2-low expressing (HER-LE) metastatic breast cancer (MBC) with brain metastases (BM) and/or leptomeningeal carcinomatosis (LMC): DEBBRAH

Marta Vaz Batista ,M Galàn Garmaje,Manuel Ruíz-Borrego ,J.M Cejalvo,Vega Iranzo ,Sònia Servitja ,Santiago González-Santiago ,Mónica Nave ,María Fernández-Abad ,J M Perez-Garcia ,Laura Lema ,S Blanch,María Gión ,Adela Fernández ,Antonio Llombart-Cussac ,Javier Cortés ,Juan De La Haba ,Patricia Cortez ,Fabricio Racca ,Sofía Braga

doi:10.1016/j.annonc.2021.08.613

330TiP Trastuzumab deruxtecan (T-DXd; DS-8201) in HER2-positive (HER2+) and HER2-low expressing (HER-LE) metastatic breast cancer (MBC) with brain metastases (BM) and/or leptomeningeal carcinomatosis (LMC): DEBBRAH

Marta Vaz Batista , M Galàn Garmaje + Show 18 more

Open Access

https://doi.org/10.1016/j.annonc.2021.08.613

Copy DOI

Journal: Annals of oncology : official journal of the European Society for Medical Oncology	Publication Date: Sep 1, 2021
Citations: 2	License type: publisher-specific-oa

#Asymptomatic Central Nervous System #Metastatic Breast Cancer + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

In the DESTINY-Breast01 study, T-DXd demonstrated a strong efficacy in HER2+ MBC patients (pts) with and without asymptomatic central nervous system (CNS) metastases. T-DXd has also showed promising antitumor activity in HER2-LE (IHC 1+ or 2+ and lack of HER2 amplification) MBC. DEBBRAH is assessing the efficacy and safety of T-DXd in HER2+ and HER2-LE MBC pts with BM and/or LMC.

Full Text